ArticleThe Journal of endocrinology2026
Triiodothyronine-driven pro-inflammatory responses of dendritic cells are restrained by sphingolipid signaling.
Article in The Journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
We previously reported that triiodothyronine (T3) promotes maturation of dendritic cells (DCs) and enhances their ability to induce pro-inflammatory and cytotoxic T-cell responses through Akt signaling. However, the underlying mechanisms remain incompletely understood. Sphingosine-1-phosphate (S1P), a bioactive sphingolipid, is implicated under several pro-inflammatory conditions. Here, we investigated the role of sphingosine kinase 1 (SK1), S1P, and its receptors (S1PRs) in the immunomodulatory effects of T3 on DCs and the ensuing adaptive immune response. DCs were generated from the bone marrow of C57BL/6 wild-type or SK1 knockout mice and stimulated with T3 (T3-DC). To modulate the S1P pathway, PF-543 (SK1 inhibitor), S1P, or FTY720 (S1PR functional antagonist) was added prior to T3. Phosphorylated Akt (p-Akt) and phosphorylated STAT3 (p-STAT3) were analyzed by Western blotting. Splenocytes from BALB/c mice were co-cultured with DCs under SK1 or S1PR inhibition and exposed to T3. Cell markers and proliferation were evaluated by flow cytometry, and cytokines were measured by flow cytometry and ELISA. We show that the SK1/S1P/S1PR pathway regulates IL-12p70 production in T3-DC, while S1PRs also modulate IL-6 secretion. Mechanistically, S1P signaling mediates T3-induced Akt phosphorylation in DCs. STAT3 activation was observed in T3-DC and was not altered by inhibition of SK1 or S1PR. Although the SK1/S1P/S1PR axis did not alter T cell proliferation, S1PR inhibition increased IFN-γ, and inhibition of either SK1 or S1PRs enhanced IL-17 secretion by splenocytes. Altogether, these findings suggest that a complex sphingolipid-mediated signaling network modulates the immunostimulatory effects of T3 on DCs and the driven adaptive immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.